Patents by Inventor Kim Askew

Kim Askew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITION AND METHODS FOR TREATMENT OF METHYLMALONIC ACIDEMIA
    Publication number: 20230145188
    Abstract: The present invention provides, among other things, methods and compositions for treating methylmalonic academia (MMA) based on mRNA therapy. The compositions used in treatment of MMA comprise an mRNA comprising a methymalonyl-CoA mutase (MUT) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of MMA is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized MUT coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.
    Type: Application
    Filed: September 13, 2019
    Publication date: May 11, 2023
    Inventors: Lianne Boeglin, Christian Cobaugh, Frank DeRosa, Michael Heartlein, Kim Askew
  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20220354933
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: May 18, 2022
    Publication date: November 10, 2022
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • Methods of treating myointimal proliferation
    Patent number: 11364284
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: June 21, 2022
    Assignees: Inozyme Pharma, Inc., Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Yan Yan, Anumeha Shah, Ashmita Saigal, Herman Griffin, Susan Faas McKnight, Andre Marozsan, Kim Askew, Yvonne Nitschke, Frank Rutsch
  • Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
    Publication number: 20220072152
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Application
    Filed: September 27, 2021
    Publication date: March 10, 2022
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
  • Composition and methods for treatment of ornithine transcarbamylase deficiency
    Patent number: 11167043
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: November 9, 2021
    Assignee: TRANSLATE BIO, INC.
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier
  • METHODS OF TREATING MYOINTIMAL PROLIFERATION
    Publication number: 20200306349
    Abstract: The present invention provides a method of treating myointimal proliferation by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 1, 2020
    Inventors: Yan YAN, Anumeha SHAH, Ashmita SAIGAL, Herman GRIFFIN, Susan Faas MCKNIGHT, Andre MAROZSAN, Kim ASKEW, Yvonne NITSCHKE, Frank RUTSCH
  • METHODS OF IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING A RECOMBINANT ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE (NPP1)
    Publication number: 20200263153
    Abstract: The present invention provides methods for improving cardiovascular function in a human patient (e.g., reducing hypertension), as well as methods of treating a cardiovascular disease, by administering a recombinant human soluble ectonucleotide pyrophosphatase phosphodiesterase (hsNPP1), active fragment or fusion protein thereof.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 20, 2020
    Inventors: Tayeba KHAN, Andre MAROZSAN, Kim ASKEW
  • Composition and Methods for Treatment of Ornithine Transcarbamylase Deficiency
    Publication number: 20190192688
    Abstract: The present invention provides, among other things, methods of treating ornithine transcarbamylase deficiency, including administering to a subject in need of treatment a composition comprising an mRNA encoding an ornithine transcarbamylase protein at a low dose and at an administration interval such that at least one symptom or feature of the OTC deficiency is reduced.
    Type: Application
    Filed: December 20, 2018
    Publication date: June 27, 2019
    Inventors: Kim Askew, Jou-Ku Chung, Frank DeRosa, Michael Heartlein, Shrirang Karve, Thomas McCauley, Lianne Smith, Ann J. Barbier